Intraocular Amphiregulin antibody and axial elongation in nonhuman primates.

To examine the effect of intraocularly applied amphiregulin antibody on physiological axial elongation in young nonhuman primates. The experimental study included six male 12-months-old macaque nonhuman primates (body weight:2.46 ± 0.25kg;range:2.20-2.90kg). In the experimental group (n=3 animals), three intravitreal injections of amphiregulin antibody (100μg/50μl) were applied to the left eyes at intervals of 4-6 weeks, and injections of phosphate buffered solution (50μl) were applied to the right eyes. Three other animals were assigned to a blank control group. During the study period of 23.6 weeks, axial length in the experimental group did not change in the left eyes (18.91 ± 0.37mm to 18.94 ± 0.67mm; Intraocularly applied amphiregulin antibody (100μg) reduced the physiological ocular axial elongation in juvenile nonhuman primates.

Informations de copyright

Copyright © 2022 Wang, Nan, Huang, Pu and Jonas.

Déclaration de conflit d'intérêts

JJ holds European patent EP 3 271 392, JP 2021-119187, and US 11,008,385: “Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia, and has Patent application: European patent application: WO 2021/198369 A1; PCT/EP2021/058500: Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium-associated diseases. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.